Ezetimibe, a selective inhibitor of the transport of cholesterol

Internal Medicine

Volumn 47, Issue 13, 2008, Pages 1165-1170

  Miura, Shin Ichiro ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cholesterol absorption; Ezetimibe; Niemann Pick C1 like 1

Indexed keywords

ATORVASTATIN; EZETIMIBE; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEMBRANE PROTEIN; NIEMANN PICK DISEASE C1 LIKE 1 PROTEIN; PLACEBO; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; AZETIDINE DERIVATIVE; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; NPC1L1 PROTEIN, HUMAN;

CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; CHROMOSOME 7P; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GLUCOSE METABOLISM; HETEROZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MONOTHERAPY; NIEMANN PICK DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; DRUG COMBINATION; DRUG EFFECT; METABOLISM; MOUSE; PROTEIN SECONDARY STRUCTURE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; HYPERCHOLESTEROLEMIA; MEMBRANE PROTEINS; MICE; PROTEIN STRUCTURE, SECONDARY;

EID: 49649108596     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.1099     Document Type: Review

References (40)

1. Grundy SM. Absorption and metabolism of dietary cholesterol. Annu Rev Nutr 3: 71-96, 1983.
2. Clader JW. The discovery of ezetimibe: a view from outside the receptor. J Med Chem 47: 1-9, 2004.
3. Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303: 1201-1204, 2004.
4. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A 102: 8132-8137, 2005.
5. Ioannou YA. The structure and function of the Niemann-Pick C1 protein. Mol Genet Metab 71: 175-181, 2000.
6. Iyer SP, Yao X, Crona JH, et al. Characterization of the putative native and recombinant rat sterol transporter Niemann-Pick C1 Like 1 (NPC1L1) protein. Biochim Biophys Acta 1722: 282-292, 2005.
7. Davies JP, Levy B, Ioannou. YA. Evidence for a Niemann-pick C (NPC) gene family: identification and characterization of NPC1L 1. Genomics 65: 137-145, 2000.
8. Hauser H, Dyer JH, Nandy A, et al. Identification of a receptor mediating absorption of dietary cholesterol in the intestine. Biochemistry 37: 17843-17850, 1998.
9. Dixit SS, Sleat DE, Stock AM, et al. Do mammalian NPC1 and NPC2 play a role in intestinal cholesterol absorption? Biochem J 408: 1-5, 2007.
10. Labonté ED, Howles PN, Granholm NA, et al. Class B type I scavenger receptor is responsible for the high affinity cholesterol binding activity of intestinal brush border membrane vesicles. Biochim Biophys Acta 1771: 1132-1139, 2007.
11. Davis HR Jr, Zhu LJ, Hoos LM, et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 279: 33586-33592, 2004.
12. Duval C, Touche V, Tailleux A, et al. Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochem Biophys Res Commun 340: 1259-1263, 2006.
13. Smith MM, Levitan DJ. Human NPC1L1 and NPC1 can functionally substitute for the ncr genes to promote reproductive development in C. elegans. Biochim Biophys Acta 1770: 1345-1351, 2007.
14. Tang W, Ma Y, Jia L, Ioannou YA, Davies JP, Yu L. Niemann-Pick C1-Like 1 is required for an LXR agonist to raise plasma HDL cholesterol in mice. Arterioscler Thromb Vasc Biol 28: 448-454, 2008.
15. Liu R, Iqbal J, Yeang C, et al. Phospholipid transfer protein-deficient mice absorb less cholesterol. Arterioscler Thromb Vasc Biol 27: 2014-2021, 2007.
16. van der Veen JN, Kruit JK, Havinga R, et al. Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J Lipid Res 46: 526-534, 2005.
17. Lally S, Owens D, Tomkin GH. The different effect of pioglitazone as compared to insulin on expression of hepatic and intestinal genes regulating post-prandial lipoproteins in diabetes. Atherosclerosis 193: 343-351, 2007.
18. Lally S, Tan CY, Owens D, et al. Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia 49: 1008-1016, 2006.
19. Seedorf U, Engel T, Lueken A, et al. Cholesterol absorption inhibitor Ezetimibe blocks uptake of oxidized LDL in human macrophages. Biochem Biophys Res Commun 320: 1337-1341, 2004.
20. Valasek MA, Clarke SL, Repa JJ. Fenofibrate reduces intestinal cholesterol absorption via PPAR(alpha)-dependent modulation of NPC1L1 expression in mouse. J Lipid Res 48: 2725-2735, 2007.
21. Temel RE, Tang W, Ma Y, et al. Hepatic: Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 117: 1968-1978, 2007.
22. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A 102: 8132-8137, 2005.
23. Deushi M, Nomura M, Kawakami A, et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 581: 5664-5670, 2007.
24. van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 129: 1748-1754, 2000.
25. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 40: 2125-2134, 2002.
26. Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 23: 1169-1176, 2007.
27. Gagné C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 90: 1084-1091, 2002.
28. Gaudiani LM, Lewin A, Meneghini L, et al. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab 7: 88-97, 2005.
29. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107: 2409-2415, 2003.
30. Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 99: 673-680, 2007.
31. Telford DE, Sutherland BG, Edwards JY, et al. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. J Lipid Res 48: 699-708, 2007.
32. McKenney JM, Farnier M, Lo KW, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 47: 1584-1587, 2006.
33. Farnier M, Roth E, Gil-Extremera B, et al. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J 153 (335): e1-e8, 2007.
34. Wang J, Williams CM, Hegele RA. Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe. Clin Genet 67: 175-177, 2005.
35. Simon JS, Kamoub MC, Devlin DJ, et al. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics 86: 648-656, 2005.
36. Cohen JC, Pertsemlidis A, Fahmi S, et al. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci U S A 103: 1810-1805, 2006.
37. Davidson MH, Ballantyne CM, Kerzner B, et al. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 58: 746-755, 2004.
38. Goldberg AC, Sapre A, Liu J, et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 79: 620-629, 2004.
39. Lipka L, Sager P, Strony J, et al. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging 21: 1025-1032, 2004.
40. de Jongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 106: 2231-2237, 2002.